| DB ID | MyCo_3101 |
| Title | Serum (1 → 3)-β-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value |
| Year | 2011 |
| PMID | 20673271 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | Here conducted a retrospective study on 50 patients with PJP and 50 immunocompromised control patients to evaluate the diagnostic performance of serum BG measurement. |
| Cohort No. | 50 Patients and 50 control |
| Age Group | Apr-83 |
| P Value | p<0.001 |
| Sensitivity | 0.98 |
| Specificity | 0.94 |
| Positive Predictive Value | 0.647 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis jirovecii (carinii) pneumonia (PJP) is a major cause of mortality in immunocompromised individuals. Therefore, early diagnosis and therapy is vital. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
